News & Reports

Have some news you want to share with the Oregon Bio community?  Fill out our submission form.

Thermo Fisher Scientific : Expects 2020 Revenue to Grow 20%

By Dave Sebastian – https://www.marketscreener.com/quote/stock/THERMO-FISHER-SCIENTIFIC-14623/news/Thermo-Fisher-Scientific-Expects-2020-Revenue-to-Grow-20-31583605/

Thermo Fisher Scientific Inc. executives said the company expects 2020 revenue to grow 20% to about $30.52 billion, its first full-year outlook since it withdrew guidance in April due to Covid-19 uncertainty.

The scientific-equipment and diagnostics company also expects adjusted earnings to rise 48% to $18.27 a share for the year, executives said on a conference call Wednesday.

The estimates are higher than the outlook it put out in late January, when it guided for adjusted earnings […]

October 26, 2020 |

US FDA approves Gilead’s antiviral Veklury®(Remdesivir) for treatment of COVID-19

— Veklury Is First and Only FDA-Approved Treatment for COVID-19 in the United States —
— Veklury Shortened Time to Recovery By Five Days in Hospitalized COVID-19 Patients —

Gilead Sciences, Inc. (Nasdaq: GILD) announced on Oct. 22 that the U.S. Food and Drug Administration (FDA) has approved the antiviral drug Veklury® (remdesivir) for the treatment of patients with COVID-19 requiring hospitalization. As an antiviral drug, Veklury works to stop replication of SARS-CoV-2, the virus that causes COVID-19. Previously authorized by the […]

Covid drives historic demand for life sciences real estate and these REITs, report says

Credit: https://www.cnbc.com/2020/10/09/covid-19-drives-historic-demand-for-life-sciences-real-estate-.html

All the fundamentals are aligning for the life sciences industry, as Covid-19 accelerates already growing demand for real estate in the sector.

Rents are rising for lab space, vacancies are plunging and research and development, and employment and new development are expanding further, thanks to strong venture capital investment.

In the top life sciences markets there’s currently about 13.9 million square feet of space under construction, but active tenant demand is outpacing that, running at about 14.7 million square feet, according […]

October 13, 2020 |

Get discovered – Calling bio researchers and entrepreneurs to pitch, apply by October 7th

The Oregon Bioscience Association invites high school through post-doctoral researchers as well as bio entrepreneurs leading early- and later-stage startups from Oregon and Southwest Washington to compete in Oregon Bio’s expanded pitch events. Scientists and companies in the areas of biopharma, medical device, diagnostics and digital health are eligible. Entrants are asked to show how their work/intel explores a current bio-problem and what solutional, transformative approach they’ve derived. The categories are:

Sign of things to come at Knight Campus

UO researcher’s work drives launch of spin-off, Penderia Technologies

By Matt Sayre, Contributor, The Register-Guard

The Phil and Penny Knight Campus for Accelerating Scientific Impact is not scheduled to open officially until this fall; however, there are early indicators that it could have an outsized local economic impact, as well as a broader scientific one.

Once fully staffed, the Knight Campus will be home to about 300 full-time research staff members, 250 graduate students, 150 post-doctoral researchers and 150 undergraduates.

Keat Ghee Ong, Ph.D., […]

August 7, 2020 |

Voice of Industry: Sedia 2.x: Scaling up and overcoming challenges, Part 2

Oregon Bio recently caught up with Sedia Biosciences Corp.’s two founders, Roger Gale and Ron Mink, Ph.D. to learn more – not only about how its coping with Covid-19 impacts but more about the company’s innovation strategies. Last week we ran Part 1.

Recently, Sedia worked with the City of Beaverton to relocate to expand product manufacturing capabilities to serve an increasing demand for HIV diagnostic and epidemiological assays, specifically HIV recency diagnostics. Although the company started small […]

Post-DEI event: Discussions and takeaways

Last Thursday, Oregon Bio culled together about 100 industry pros for a Diversity Dialogue around equity and inclusion. Participants from a broad range of multi-cultural backgrounds and experiences engaged with panelists Emmanuel Akporiaye, Ph.D., founder of Veana Therapeutics; Ndongo “Don” Khouma, principal validation engineer at Genentech; and Nate Miles, vice president of Strategic Initiatives, State Government Affairs at Eli Lilly & Company. Soundharya Nagasubramanian, director of R&D in Product Information […]

August 4, 2020 |

Oregon Bio hosts free, virtual diversity dialogue to address racism and health disparities

On Thursday, July 30, BIPOC leaders and life science experts will convene for Diversity Dialogue: #BeTheChange. The panelists are respected bio professionals Dr. Emmanuel Akporiaye, founder of Veana Therapeutics; Ndongo Khouma, principal validation engineer at Genentech; and Nate Miles, vice president of Strategic Initiatives in State Government Affairs at Eli Lilly and Company.  Moderating the dialogue is Soundharya Nagasubramanian, director of R&D in Product Information Security at Hillrom/Welch Allyn.

“Diversity, inclusion and belonging are an important […]

Sedia Biosciences Corporation announces expansion and move to new research and manufacturing facility in Beaverton, Oregon, USA

Expansion accommodates significant growth in demand for its new rapid point-of-care HIV tests intended to break the chain of new HIV infections worldwide

Sedia Biosciences Corporation, formerly of Portland Oregon, today announced the relocation to and opening of their new assay development and manufacturing facility in Beaverton, Oregon.  The 27,000 square foot facility provides for both current growth as well as additional near-term expansion and enables immediate scale-up of manufacturing capacity as well as research capabilities.  Equipped with multiple state of […]

August 3, 2020 |

Voice of Industry: Sedia 2.x: Expansion, relocation and scaling up tracks growth, Part 1

Oregon Bio recently caught up with Sedia Biosciences Corp.’s founders Roger Gale and Ron Mink, Ph.D. to learn more about the company’s growth and innovation strategies.

Recently, Sedia worked with the City of Beaverton to relocate to expand product manufacturing capabilities to serve an increasing demand for HIV diagnostic and epidemiological assays, specifically HIV recency diagnostics. Although the company started small in Portland in 2009, just a decade later it now counts 40 employees (and growing), serving global […]